ImmunoVaccine Technologies Inc. (IVT), a Nova Scotia-based vaccine enhancement company, has signed a binding memorandum of understanding to acquire Immunotope Inc., a Pennsylvania-based biotechnology company developing immunotherapy products for the treatment and prevention of cancer and infectious diseases.
Innovacorp welcomes the Association of Internationally Educated and Trained Professionals of Nova Scotia (IETP - NS) to the Technology Innovation Centre.
The staff and clients of Innovacorp welcome our newest client, Connecting People for Health Co-operative Ltd. (CPHCi).
CPHCi is committed to connecting people to the health care system and to communities of support through the use of information technology. CPHCi believes that an empowered and supported patient improves individual, family, and community health and well-being, and can eventually transform the delivery of health care.
EastMed Inc., an Atlantic Canadian medical manufacturing company that caters specifically to women's health and wellness, officially launched its very first product in Halifax today.
The uresta™ Continence Care Kit, EastMed’s flagship product designed to stop bladder leakage, is expected to empower women to self-manage their stress urinary incontinence (SUI) with a breakthrough alternative to traditional products.
Innovacorp is a proud partner in BioPort Atlantic 2007, happening September 26-27, 2007, at the World Trade and Convention Centre.
BioPort Atlantic is the annual signature event for Atlantic Canada’s life sciences industry. Presented by BioNova – The Nova Scotia Biotechnology and Life Sciences Industry Association, this exciting conference draws members of the life sciences and business communities from across North America and abroad.
A line-up of top notch speakers and panel presentations has been announced for the Atlantic region’s annual life sciences conference.
Nova Scotia Premier, Rodney MacDonald has declared the week of September 23-29, 2007 as Biotechnology and Life Sciences Week in Nova Scotia. The proclamation is being made in recognition of the growing impact that the life sciences industry has on the province’s economy and on the overall well-being of Nova Scotians.
Coemergence Inc., a leader in the development of knowledge-based software, is pleased that its ACIS solution has been recognized by KMWorld Magazine as a 2005 “Trend Setting” product.
ACIS allows companies to gain a strategic advantage over their competitors by helping to quickly identify and act on industry shifts, patterns and trends that reveal emerging opportunities and threats, before they are made public.
EastMed Inc., a medical manufacturing company that caters specifically to women's health and wellness, has received a Canadian Medical Device Licence from Health Canada for its very first product set to hit the Atlantic Canadian marketplace this fall.
The company’s flagship product, the uresta™ Continence Care Kit, empowers women to self-manage their stress urinary incontinence (SUI) with a breakthrough alternative to traditional products.
Dr. Lidija Marusic, senior advisor of business ventures with Innovacorp, has been appointed to the Canadian Institutes of Health Research (CIHR) Proof of Principle (POP) program peer review committee.
Lidija has 15 years of experience in commercialization, venture capital and academic research. She holds a Doctor of Medicine degree from the University of Zagreb in Croatia, a PhD in molecular genetics from the International School for Advanced Studies in Trieste, Italy, and an MBA from McMaster University in Hamilton, Ontario.
Coemergence Inc., a software company in the collaborative business intelligence market, has been chosen by Stanford University's AlwaysOn as one of the AO 100 Top Private Companies for 2007. AO 100 winners demonstrate leadership among their peers in the areas of innovation, market potential, customer adoption, media buzz and investor value creation.
The elite AO 100 power list was compiled by the AlwaysOn editorial panel. Coemergence was selected from over 1,000 companies, peer-nominated by leading venture investors, investment bankers and other industry experts.